PD-L1-话题@MedSci

#PD-L1#

309篇内容 | 6058人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1255136, encodeId=41c4125513674, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？, objectType=article, longId=294782, objectId=5533294e8241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5533294e8241, replyNumber=0, likeNumber=55, createdTime=2022-01-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5533294e8241, moduleTitle=PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5533294e8241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255135, encodeId=d88f12551350a, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, objectType=article, longId=294335, objectId=1c8d29433575, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c8d29433575, replyNumber=0, likeNumber=68, createdTime=2022-01-21, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c8d29433575, moduleTitle=Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c8d29433575)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255134, encodeId=58e812551347d, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=AJH：PD-L1 过表达与 JAK2-V617F 突变负担相关，并与骨髓增殖性肿瘤中的 9p 单亲二体性相关。, objectType=article, longId=293934, objectId=e987293934a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e987293934a7, replyNumber=0, likeNumber=93, createdTime=2022-01-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e987293934a7, moduleTitle=AJH：PD-L1 过表达与 JAK2-V617F 突变负担相关，并与骨髓增殖性肿瘤中的 9p 单亲二体性相关。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e987293934a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255133, encodeId=a6a61255133b2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, objectType=article, longId=293561, objectId=cf2c293561b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf2c293561b4, replyNumber=0, likeNumber=69, createdTime=2022-01-09, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf2c293561b4, moduleTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf2c293561b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255132, encodeId=51b0125513256, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=【收藏】PD-1/PD-L1药物(NMPA/FDA)获批适应症, objectType=article, longId=293239, objectId=482e29323925, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=482e29323925, replyNumber=0, likeNumber=80, createdTime=2022-01-03, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=482e29323925, moduleTitle=【收藏】PD-1/PD-L1药物(NMPA/FDA)获批适应症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=482e29323925)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255131, encodeId=2925125513145, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=一图读懂中国PD-1/PD-L1 | 2021.12, objectType=article, longId=292832, objectId=c8e7292832c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8e7292832c1, replyNumber=0, likeNumber=0, createdTime=2021-12-29, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8e7292832c1, moduleTitle=一图读懂中国PD-1/PD-L1 | 2021.12, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8e7292832c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255130, encodeId=e831125513059, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, objectType=article, longId=292494, objectId=9f45292494ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f45292494ff, replyNumber=0, likeNumber=60, createdTime=2021-12-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f45292494ff, moduleTitle=Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f45292494ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255129, encodeId=beec1255129fe, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=罗氏PD-L1+TIGIT双靶用于一线NSCLC治疗，效果惊艳，OS死亡风险降低71%, objectType=article, longId=264997, objectId=3fc926499ed5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3fc926499ed5, replyNumber=0, likeNumber=85, createdTime=2021-12-14, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3fc926499ed5, moduleTitle=罗氏PD-L1+TIGIT双靶用于一线NSCLC治疗，效果惊艳，OS死亡风险降低71%, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3fc926499ed5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255128, encodeId=85e212551286f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Clin Oncol：PD-L1低表达的晚期胃或食管腺癌(GEAC)患者免疫检查点抑制剂（ICI）的疗效, objectType=article, longId=221539, objectId=ea642215396a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ea642215396a, replyNumber=0, likeNumber=63, createdTime=2021-12-06, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ea642215396a, moduleTitle=J Clin Oncol：PD-L1低表达的晚期胃或食管腺癌(GEAC)患者免疫检查点抑制剂（ICI）的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ea642215396a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255127, encodeId=5104125512ea8, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, objectType=article, longId=221205, objectId=3c79221205ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c79221205ea, replyNumber=0, likeNumber=95, createdTime=2021-11-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c79221205ea, moduleTitle=J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c79221205ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255126, encodeId=ec0d1255126e3, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cancers (Basel)：使用机器学习模型研究接受PD-1或PD-L1抑制剂患者甲状腺相关不良事件的相关因素, objectType=article, longId=221104, objectId=afbf22110424, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=afbf22110424, replyNumber=0, likeNumber=64, createdTime=2021-11-28, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=afbf22110424, moduleTitle=Cancers (Basel)：使用机器学习模型研究接受PD-1或PD-L1抑制剂患者甲状腺相关不良事件的相关因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=afbf22110424)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255125, encodeId=038e12551255b, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=胃癌组织中IL-6、STT3A和PD-L1的表达及临床意义, objectType=article, longId=221049, objectId=1c9c22104932, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c9c22104932, replyNumber=0, likeNumber=67, createdTime=2021-11-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c9c22104932, moduleTitle=胃癌组织中IL-6、STT3A和PD-L1的表达及临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c9c22104932)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255124, encodeId=319f1255124c1, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=胃癌中 TGF-β、 PD-L1 表达与肿瘤免疫表型的关系及其临床意义, objectType=article, longId=221048, objectId=fc0c22104810, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc0c22104810, replyNumber=0, likeNumber=59, createdTime=2021-11-27, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc0c22104810, moduleTitle=胃癌中 TGF-β、 PD-L1 表达与肿瘤免疫表型的关系及其临床意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc0c22104810)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255123, encodeId=3fd61255123a2, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, objectType=article, longId=220988, objectId=1236220988e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1236220988e5, replyNumber=0, likeNumber=66, createdTime=2021-11-26, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1236220988e5, moduleTitle=不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1236220988e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255122, encodeId=2a9c12551229f, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Clin Cancer Res：PD-L1抗体单药或联合TIM-3抗体在MSI-H/dMMR晚期肿瘤中的抗肿瘤活性和安全性, objectType=article, longId=220797, objectId=5c23220e97c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c23220e97c1, replyNumber=0, likeNumber=80, createdTime=2021-11-23, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c23220e97c1, moduleTitle=Clin Cancer Res：PD-L1抗体单药或联合TIM-3抗体在MSI-H/dMMR晚期肿瘤中的抗肿瘤活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c23220e97c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255121, encodeId=aaf3125512118, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, objectType=article, longId=220461, objectId=b29d2204611e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b29d2204611e, replyNumber=0, likeNumber=25, createdTime=2021-11-18, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b29d2204611e, moduleTitle=Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b29d2204611e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255120, encodeId=8022125512015, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, objectType=article, longId=219447, objectId=234a21944e5a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=234a21944e5a, replyNumber=0, likeNumber=0, createdTime=2021-10-30, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=234a21944e5a, moduleTitle=Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=234a21944e5a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255119, encodeId=f41d1255119cf, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制, objectType=article, longId=218860, objectId=c4e02188600e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c4e02188600e, replyNumber=0, likeNumber=79, createdTime=2021-10-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c4e02188600e, moduleTitle=Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c4e02188600e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255118, encodeId=a571125511837, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, objectType=article, longId=217312, objectId=e46321e31264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46321e31264, replyNumber=0, likeNumber=93, createdTime=2021-09-20, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46321e31264, moduleTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46321e31264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1255117, encodeId=e77e125511e04, content=<a href='/topic/show?id=be71139214f' target=_blank style='color:#2F92EE;'>#PD-L1#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=29, createdTime=2021-09-13, rootId=0, userName=smartjoy, userId=e76f39, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-L1

2020-05-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

PD-L1高表达（90%）的晚期NSCLC免疫+含铂双药化疗效果不好是什么原因？下一步治疗方法是什么？

2022-01-28

zhaojie88 (审核中...)

前往app查看评论内容

#PD-L1#

Front Oncol：PD-L1高表达是肝细胞癌患者手术切除后索拉非尼辅助治疗后复发的独立预测因素

2022-01-21

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

AJH：PD-L1 过表达与 JAK2-V617F 突变负担相关，并与骨髓增殖性肿瘤中的 9p 单亲二体性相关。

2022-01-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS

2022-01-09

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

【收藏】PD-1/PD-L1药物(NMPA/FDA)获批适应症

2022-01-03

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

一图读懂中国PD-1/PD-L1 | 2021.12

2021-12-29

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Chest：支气管超声引导下针吸穿刺(EBUS-TBNA)获得的标本检测PD-L1表达同样可指导PD1抑制剂在晚期NSCLC患者中的应用

2021-12-23

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

罗氏PD-L1+TIGIT双靶用于一线NSCLC治疗，效果惊艳，OS死亡风险降低71%

2021-12-14

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Clin Oncol：PD-L1低表达的晚期胃或食管腺癌(GEAC)患者免疫检查点抑制剂（ICI）的疗效

2021-12-06

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

J Immunother Cancer：PD-L1抑制剂avelumab联合/不联合西妥昔单抗治疗既往治疗过的晚期肛管鳞状细胞癌(aSCAC)患者的疗效和安全性：CARACAS研究

2021-11-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cancers (Basel)：使用机器学习模型研究接受PD-1或PD-L1抑制剂患者甲状腺相关不良事件的相关因素

2021-11-28

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

胃癌组织中IL-6、STT3A和PD-L1的表达及临床意义

2021-11-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

胃癌中 TGF-β、 PD-L1 表达与肿瘤免疫表型的关系及其临床意义

2021-11-27

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

不可切除III期非小细胞肺癌迎来免疫治疗新时代！PD-L1单抗在中国获批！

2021-11-26

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Clin Cancer Res：PD-L1抗体单药或联合TIM-3抗体在MSI-H/dMMR晚期肿瘤中的抗肿瘤活性和安全性

2021-11-23

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Nat Med：PD-L1抑制剂durvalumab联合铂类+培美曲塞治疗既往未治、不能切除的恶性胸膜间皮瘤(MPM)的疗效和安全性：II期临床研究PrE0505

2021-11-18

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Eur Urol：ccRCC患者中，PARP1预测PD-L1阻断治疗反应的效果如何？

2021-10-30

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Cancer Cell：张泽民团队等揭示抗PD-L1免疫治疗联合化疗在三阴性乳腺癌中的作用机制

2021-10-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究

2021-09-20

smartjoy (审核中...)

前往app查看评论内容

#PD-L1#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2021-09-13

科室
- - 订阅+
  - 更多科室
工具
服务